Patent ID: 11897872
Assignee: JANSSEN PHARMACEUTICA NV
Field: Organic fine chemistry (Chemistry)
Classification: CPC C  A | IPC C

Claim 0:
1. A method of treating a subject suffering from or diagnosed with a disease, disorder, or condition mediated by MGL receptor activity, comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of Formula (I):, wherein
X is CH2 or O;
R1 is H;
R2a and R2b are each independently selected from H and C1-4alkyl;
R3 is selected from:
(i) phenyl, benzyl, or monocyclic heteroaryl, each optionally substituted with one, two, or three substituents selected from: halo, C1-6alkyl, C1-6haloalkyl, C1-6alkyl-OH, OC1-6alkyl, OC1-6haloalkyl, SC1-6alkyl, SF5, Si(CH3)3, NRaRb, C3-6cycloalkyl, OC3-6cycloalkyl, phenyl, O-phenyl, and O-pyridyl, wherein each cycloalkyl, phenyl, or pyridyl is optionally substituted with one or two C1-4alkyl, C1-4haloalkyl, or halo groups; or two adjacent ring substituents on the phenyl, benzyl, or monocyclic heteroaryl, taken together with the atoms to which they are attached form a fused monocyclic C5-6cycloalkyl or heterocycloalkyl ring, each ring optionally substituted with one or two C1-4alkyl, C1-4haloalkyl, or halo groups;
wherein Ra and Rb are each independently H or C1-4alkyl;

(ii) a bicyclic heteroaryl optionally substituted with C1-4alkyl or halo; and
(iii) C3-6alkyl or C3-6cycloalkyl optionally substituted with C1-4alkyl, C1-4haloalkyl, or halo; and

n, m, o, and p are each independently 1 or 2;
or a pharmaceutically acceptable salt, isotope, N-oxide, or stereoisomer thereof.